Total and Unbound Pharmacokinetics of Cefiderocol in Critically Ill Patients [PDF]
Pharmaceutics, 2022 Background: Cefiderocol is a siderophore cephalosporin antibiotic active against Gram-negative bacteria, including extended-spectrum beta-lactamase and carbapenemase-producing strains.
Noël Zahr +11 more
doaj +2 more sources
Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol [PDF]
Clinical Pharmacokinetics, 2021 Cefiderocol is a new broad-spectrum cephalosporin antibiotic with promising activity against various Gram-negative bacteria including carbapenem-resistant strains. A chlorocatechol group in the C-3 side chain provides cefiderocol with a siderophore activity, improving its stability against β-lactamases and facilitating the transportation of cefiderocol
Muhammad Bilal +5 more
openaire +4 more sources
Antibacterial spectrum of cefiderocol [PDF]
Revista Española de Quimioterapia, 2022 Cefiderocol, a siderophore catechol cephalosporin, recently introduced in the market has been developed to enhance the in vitro activity of extended spectrum cephalosporins and to avoid resistance mechanisms affecting cephalosporins and carbapenems. The in vitro study of cefiderocol in the laboratory requires iron depleted media when MIC values are ...
Cordero, Desirée Gijón +3 more
openaire +3 more sources
Clinical Outcome of Cefiderocol for Infections with Carbapenem-Resistant Organisms [PDF]
Antibiotics, 2023 Cefiderocol is a novel cephalosporin recently approved by the FDA to aid clinicians in the fight against multidrug-resistant (including carbapenem-resistant) gram-negative organisms.
Monirul I. Sajib +2 more
doaj +2 more sources
Clinical experience of cefiderocol [PDF]
Revista Española de Quimioterapia, 2022 Infections by antibiotic-resistant microorganisms could be considered a “stealth pandemic” that we fight daily in most hospitals. Some estimates suggest that today 700,000 deaths per year can be attributed to antimicrobial resistance. By the year 2050, it is estimated that this will increase to ten million deaths per year as a result of infections by ...
Fariñas Álvarez, María del Carmen +1 more
openaire +5 more sources
Population Analysis of Escherichia coli Sequence Type 361 and Reduced Cefiderocol Susceptibility, France [PDF]
Emerging Infectious Diseases, 2023 Cefiderocol resistance is increasingly reported in New Delhi metallo-β-lactamase–producing Enterobacterales. Genomic and phenotypic analysis of Escherichia coli sequence type 361, a primary clone causing carbapenemase spread in France, revealed ...
Agnès B. Jousset +11 more
doaj +2 more sources
Disc Diffusion and ComASP® Cefiderocol Microdilution Panel to Overcome the Challenge of Cefiderocol Susceptibility Testing in Clinical Laboratory Routine [PDF]
Antibiotics, 2023 Cefiderocol susceptibility testing represents a major challenge for clinical microbiology. Although disc diffusion showed robustness to test cefiderocol susceptibility, large areas of technical uncertainty (ATU) are reported by current EUCAST breakpoints.
Gabriele Bianco +5 more
doaj +3 more sources
Reduce susceptibility to cefiderocol in gram negative bacteria in children: Is hope already lost before it’s even arrived? [PDF]
Journal of Infection and Public HealthBackground: In last years the diffusion of carbapenem resistance in Gram-negative bacteria (CR-GNB) is increasing worldwide, mainly due to the expression of carbapenemases.
Chiara Russo +9 more
doaj +4 more sources
Cefiderocol for treatment of an empyema due to extensively drug-resistant Pseudomonas aeruginosa: Clinical observations and susceptibility testing considerations [PDF]
IDCases, 2020 Cefiderocol is a novel siderophore cephalosporin antibacterial with activity against carbapenem-resistant Gram-negative bacteria including Pseudomonas aeruginosa.
Wesley D. Kufel +5 more
doaj +2 more sources
Synergistic Activity of Cefiderocol in Combination with Avibactam, Sulbactam or Tazobactam against Carbapenem-Resistant Gram-Negative Bacteria [PDF]
CellsWe investigated the activity of cefiderocol/β-lactamase inhibitor combinations against clinical strains with different susceptibility profiles to cefiderocol to explore the potentiality of antibiotic combinations as a strategy to contain the major public
Russell E. Lewis +5 more
doaj +2 more sources